{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:50Z","timestamp":1792782890565,"version":"4.5.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal","id":[{"id":"https:\/\/ror.org\/02xzytt36","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02256-7","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:44:28Z","timestamp":1784565868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies"],"prefix":"10.1007","volume":"26","author":[{"given":"Navas Shereef","family":"Ellyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel Treasa","family":"Alex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha Yogendra","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3116-9610","authenticated-orcid":false,"given":"Rahul","family":"K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"5","key":"2256_CR1","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/1055-9965.EPI-20-1193","volume":"30","author":"SC Houghton","year":"2021","unstructured":"Houghton SC, Hankinson SE. Cancer Progress and Priorities: Breast Cancer. Cancer Epidemiology. Biomarkers Prev. 2021;30(5):822\u201344. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-1193.","journal-title":"Biomarkers Prev"},{"key":"2256_CR2","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674. https:\/\/doi.org\/10.1136\/bmj-2022-071674 . PubMed PMID: 37253507.","journal-title":"BMJ"},{"issue":"4","key":"2256_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/cancers15041320","volume":"15","author":"B Kinnel","year":"2023","unstructured":"Kinnel B, Singh SK, Oprea-Ilies G, Singh R. Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. Cancers. 2023;15(4):4. https:\/\/doi.org\/10.3390\/cancers15041320.","journal-title":"Cancers"},{"key":"2256_CR4","doi-asserted-by":"publisher","unstructured":"Hanna A, Balko JM. Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Res Treat. 2021;190(1):5\u201317. https:\/\/doi.org\/10.1007\/s10549-021-06337-x. PubMed PMID: 34322780; PubMed Central PMCID: PMC8560575.","DOI":"10.1007\/s10549-021-06337-x"},{"issue":"7931","key":"2256_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-05068-3","volume":"610","author":"F Andre","year":"2022","unstructured":"Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, et al. Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022;610(7931):343\u20138. https:\/\/doi.org\/10.1038\/s41586-022-05068-3.","journal-title":"Nature"},{"issue":"22","key":"2256_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms222212292","volume":"22","author":"ER Scheidemann","year":"2021","unstructured":"Scheidemann ER, Shajahan-Haq AN. Resistance to CDK4\/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Int J Mol Sci. 2021;22(22):22. https:\/\/doi.org\/10.3390\/ijms222212292.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2256_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40364-024-00653-2","volume":"12","author":"J Li","year":"2024","unstructured":"Li J, Jia Z, Dong L, Cao H, Huang Y, Xu H, et al. DNA damage response in breast cancer and its significant role in guiding novel precise therapies. Biomark Res. 2024;12(1):111. https:\/\/doi.org\/10.1186\/s40364-024-00653-2.","journal-title":"Biomark Res"},{"issue":"3","key":"2256_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/cancers18030412","volume":"18","author":"S Figueroa","year":"2026","unstructured":"Figueroa S, Reyes N, Tiwari RK, Geliebter J. Targeting the Tumor Microenvironment in Triple-Negative Breast Cancer: Emerging Roles of Monoclonal Antibodies and Immune Modulation. Cancers. 2026;18(3):412. https:\/\/doi.org\/10.3390\/cancers18030412.","journal-title":"Cancers"},{"issue":"11","key":"2256_CR9","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3390\/diagnostics13111949","volume":"13","author":"B El Hejjioui","year":"2023","unstructured":"El Hejjioui B, Lamrabet S, Amrani Joutei S, Senhaji N, Bouhafa T, Malhouf MA, et al. New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer. Diagnostics. 2023;13(11):1949. https:\/\/doi.org\/10.3390\/diagnostics13111949.","journal-title":"Diagnostics"},{"issue":"8","key":"2256_CR10","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/biomedicines10081987","volume":"10","author":"MB Firnau","year":"2022","unstructured":"Firnau MB, Brieger A. CK2 and the Hallmarks of Cancer. Biomedicines. 2022;10(8):1987. https:\/\/doi.org\/10.3390\/biomedicines10081987.","journal-title":"Biomedicines"},{"key":"2256_CR11","doi-asserted-by":"publisher","unstructured":"Chen L, Zhang S, Li Q, Li J, Deng H, Zhang S, et al. Emerging role of Protein Kinase CK2 in Tumor immunity. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.1065027.","DOI":"10.3389\/fonc.2022.1065027"},{"issue":"2","key":"2256_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/kinasesphosphatases2020007","volume":"2","author":"S Day-Riley","year":"2024","unstructured":"Day-Riley S, West RM, Brear PD, Hyv\u00f6nen M, Spring DR. CK2 Inhibitors Targeting Inside and Outside the Catalytic Box. Kinases Phosphatases. 2024;2(2):2. https:\/\/doi.org\/10.3390\/kinasesphosphatases2020007.","journal-title":"Kinases Phosphatases"},{"issue":"12","key":"2256_CR13","doi-asserted-by":"publisher","first-page":"e115609","DOI":"10.1371\/journal.pone.0115609","volume":"9","author":"CE Ortega","year":"2014","unstructured":"Ortega CE, Seidner Y, Dominguez I. Mining CK2 in Cancer. PLoS ONE. 2014;9(12):e115609. https:\/\/doi.org\/10.1371\/journal.pone.0115609.","journal-title":"PLoS ONE"},{"issue":"2","key":"2256_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1021\/cb400771y","volume":"9","author":"G Lolli","year":"2014","unstructured":"Lolli G, Ranchio A, Battistutta R. Active Form of the Protein Kinase CK2 \u03b12\u03b22 Holoenzyme Is a Strong Complex with Symmetric Architecture. ACS Chem Biol. 2014;9(2):366\u201371. https:\/\/doi.org\/10.1021\/cb400771y.","journal-title":"ACS Chem Biol"},{"issue":"4","key":"2256_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s11010-022-04558-2","volume":"478","author":"JH Trembley","year":"2023","unstructured":"Trembley JH, Kren BT, Afzal M, Scaria GA, Klein MA, Ahmed K. Protein kinase CK2 \u2013 diverse roles in cancer cell biology and therapeutic promise. Mol Cell Biochem. 2023;478(4):899\u2013926. https:\/\/doi.org\/10.1007\/s11010-022-04558-2 . PubMed PMID: 36114992; PubMed Central PMCID: PMC9483426.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"2256_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/kinasesphosphatases1040015","volume":"1","author":"L Cesaro","year":"2023","unstructured":"Cesaro L, Zuliani AM, Bosello Travain V, Salvi M. Exploring Protein Kinase CK2 Substrate Recognition and the Dynamic Response of Substrate Phosphorylation to Kinase Modulation. Kinases Phosphatases. 2023;1(4):4. https:\/\/doi.org\/10.3390\/kinasesphosphatases1040015.","journal-title":"Kinases Phosphatases"},{"issue":"18","key":"2256_CR17","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1016\/j.yexcr.2013.09.006","volume":"319","author":"W Guo","year":"2013","unstructured":"Guo W, Hao B, Wang Q, Lu Y, Yue J. Requirement of B-Raf, C-Raf, and A-Raf for the growth and survival of mouse embryonic stem cells. Exp Cell Res. 2013;319(18):2801\u201311. https:\/\/doi.org\/10.1016\/j.yexcr.2013.09.006.","journal-title":"Exp Cell Res"},{"key":"2256_CR18","doi-asserted-by":"publisher","unstructured":"Karna SKL, Lone BA, Ahmad F, Shahi N, Pokharel YR. Silencing of the CSNK2\u03b2 gene by siRNA inhibits invasiveness and growth of MDA-MB-231 cells [Internet]. bioRxiv; 2018 [cited 2025 Jan 8]. p. 311092. Available from: https:\/\/www.biorxiv.org\/content\/https:\/\/doi.org\/10.1101\/311092v1 doi:10.1101\/311092.","DOI":"10.1101\/311092v1"},{"issue":"3","key":"2256_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/jdb10030031","volume":"10","author":"D Halloran","year":"2022","unstructured":"Halloran D, Pandit V, Nohe A. The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review. J Dev Biol. 2022;10(3):31. https:\/\/doi.org\/10.3390\/jdb10030031 . PubMed PMID: 35997395; PubMed Central PMCID: PMC9397010.","journal-title":"J Dev Biol"},{"issue":"4","key":"2256_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1357-2725(96)00142-2","volume":"29","author":"LA Pinna","year":"1997","unstructured":"Pinna LA. Protein kinase CK2. Int J Biochem Cell Biol. 1997;29(4):551\u20134. https:\/\/doi.org\/10.1016\/S1357-2725(96)00142-2.","journal-title":"Int J Biochem Cell Biol"},{"key":"2256_CR21","doi-asserted-by":"publisher","first-page":"115459","DOI":"10.1016\/j.bcp.2023.115459","volume":"210","author":"M Azari","year":"2023","unstructured":"Azari M, Bahreini F, Uversky VN, Rezaei N. Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer. Biochem Pharmacol. 2023;210:115459. https:\/\/doi.org\/10.1016\/j.bcp.2023.115459.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2256_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ph10010024","volume":"10","author":"L Ferrer-Font","year":"2017","unstructured":"Ferrer-Font L, Villama\u00f1an L, Arias-Ramos N, Vilardell J, Plana M, Ruzzene M, et al. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. Pharmaceuticals (Basel). 2017;10(1):24. https:\/\/doi.org\/10.3390\/ph10010024 . PubMed PMID: 28208677; PubMed Central PMCID: PMC5374428.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2256_CR23","doi-asserted-by":"publisher","first-page":"118620","DOI":"10.1016\/j.ejmech.2026.118620","volume":"308","author":"RM Al-Zoubi","year":"2026","unstructured":"Al-Zoubi RM, Farhan A, Hanbali B, Al-Zoubi SR, Al-Qudimat AR, Al Zoubi MS, et al. Inhibiting CK2 in breast cancer: From molecular targets to drug candidates. Eur J Med Chem. 2026;308:118620. https:\/\/doi.org\/10.1016\/j.ejmech.2026.118620.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2256_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.seminoncol.2018.04.006","volume":"45","author":"SE Perea","year":"2018","unstructured":"Perea SE, Baladr\u00f3n I, Valenzuela C, Perera Y. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation. Semin Oncol. 2018;45(1):58\u201367. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.04.006.","journal-title":"Semin Oncol"},{"issue":"1","key":"2256_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11010-011-0950-y","volume":"356","author":"SE Perea","year":"2011","unstructured":"Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, et al. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research. Mol Cell Biochem. 2011;356(1):45\u201350. https:\/\/doi.org\/10.1007\/s11010-011-0950-y.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"2256_CR26","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.chembiol.2020.12.013","volume":"28","author":"CI Wells","year":"2021","unstructured":"Wells CI, Drewry DH, Pickett JE, Tjaden A, Kr\u00e4mer A, M\u00fcller S, et al. Development of a potent and selective chemical probe for the pleiotropic kinase CK2. Cell Chem Biology. 2021;28(4):546\u2013e55810. https:\/\/doi.org\/10.1016\/j.chembiol.2020.12.013.","journal-title":"Cell Chem Biology"},{"issue":"2","key":"2256_CR27","doi-asserted-by":"publisher","first-page":"108903","DOI":"10.1016\/j.isci.2024.108903","volume":"27","author":"A Bancet","year":"2024","unstructured":"Bancet A, Frem R, Jeanneret F, Mularoni A, Bazelle P, Roelants C, et al. Cancer selective cell death induction by a bivalent CK2 inhibitor targeting the ATP site and the allosteric \u03b1D pocket. iScience. 2024;27(2):108903. https:\/\/doi.org\/10.1016\/j.isci.2024.108903.","journal-title":"iScience"},{"issue":"7","key":"2256_CR28","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1021\/acsptsci.5c00192","volume":"8","author":"I Ort\u00edn","year":"2025","unstructured":"Ort\u00edn I, Ochoa-Callejero L, Werner C, Lindenblatt D, Niefind K, Mart\u00ednez A, et al. Targeting Casein Kinase 2 and Histone Deacetylase with a Dual Inhibitor Effectively Reduces Tumor Growth in a Triple-Negative Breast Cancer Xenograft Model. ACS Pharmacol Transl Sci. 2025;8(7):2093\u2013105. https:\/\/doi.org\/10.1021\/acsptsci.5c00192.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"7","key":"2256_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/pharmaceutics15071991","volume":"15","author":"P Wi\u0144ska","year":"2023","unstructured":"Wi\u0144ska P, Wielechowska M, Koronkiewicz M, Borowiecki P. Synthesis and Anticancer Activity of Novel Dual Inhibitors of Human Protein Kinases CK2 and PIM-1. Pharmaceutics. 2023;15(7):7. https:\/\/doi.org\/10.3390\/pharmaceutics15071991.","journal-title":"Pharmaceutics"},{"issue":"15Supplement","key":"2256_CR30","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1158\/1538-7445.AM2015-4453","volume":"75","author":"A Padgaonkar","year":"2015","unstructured":"Padgaonkar A, Cosenza S, Pallela V, Subbaiah DRCV, Reddy MR, Reddy EP. Abstract 4453: The dual CK2\/TNIK inhibitor, ON108600 targets cancer stem cells and induces apoptosis of paclitaxel resistant triple-negative breast cancer cells. Cancer Res. 2015;75(15Supplement):4453. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-4453.","journal-title":"Cancer Res"},{"issue":"1","key":"2256_CR31","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1038\/s41467-021-24878-z","volume":"12","author":"K Sato","year":"2021","unstructured":"Sato K, Padgaonkar AA, Baker SJ, Cosenza SC, Rechkoblit O, Subbaiah DRCV, et al. Simultaneous CK2\/TNIK\/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nat Commun. 2021;12(1):4671. https:\/\/doi.org\/10.1038\/s41467-021-24878-z.","journal-title":"Nat Commun"},{"key":"2256_CR32","doi-asserted-by":"publisher","first-page":"115459","DOI":"10.1016\/j.bcp.2023.115459","volume":"210","author":"M Azari","year":"2023","unstructured":"Azari M, Bahreini F, Uversky VN, Rezaei N. Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer. Biochem Pharmacol. 2023;210:115459. https:\/\/doi.org\/10.1016\/j.bcp.2023.115459 . PubMed PMID: 36813121.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2256_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12282-022-01415-4","volume":"30","author":"HM Nguyen","year":"2023","unstructured":"Nguyen HM, Paulishak W, Oladejo M, Wood L. Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches. Breast Cancer. 2023;30(2):167\u201386. https:\/\/doi.org\/10.1007\/s12282-022-01415-4.","journal-title":"Breast Cancer"},{"issue":"7586","key":"2256_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413\u20137. https:\/\/doi.org\/10.1038\/nature16508.","journal-title":"Nature"},{"issue":"9","key":"2256_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1177\/1947601911432496","volume":"2","author":"V Ossovskaya","year":"2011","unstructured":"Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, Potapova O, et al. Exploring Molecular Pathways of Triple-Negative Breast Cancer. Genes Cancer. 2011;2(9):870\u20139. doi:10.1177\/1947601911432496 PubMed PMID: 22593799; PubMed Central PMCID: PMC3352156.","journal-title":"Genes Cancer"},{"issue":"4","key":"2256_CR36","doi-asserted-by":"publisher","first-page":"152874","DOI":"10.1016\/j.prp.2020.152874","volume":"216","author":"K Yu","year":"2020","unstructured":"Yu K, Rohr J, Liu Y, Li M, Xu J, Wang K, et al. Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets. Pathol - Res Pract. 2020;216(4):152874. https:\/\/doi.org\/10.1016\/j.prp.2020.152874.","journal-title":"Pathol - Res Pract"},{"key":"2256_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jare.2023.02.005","volume":"54","author":"H Kumar","year":"2023","unstructured":"Kumar H, Gupta NV, Jain R, Madhunapantula SV, Babu CS, Kesharwani SS, et al. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. J Adv Res. 2023;54:271\u201392. https:\/\/doi.org\/10.1016\/j.jare.2023.02.005.","journal-title":"J Adv Res"},{"key":"2256_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CMAR.S316700","volume":"14","author":"Y Fan","year":"2022","unstructured":"Fan Y, He S. The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. CMAR. 2022;141\u201317. https:\/\/doi.org\/10.2147\/CMAR.S316700.<\\\/p>","journal-title":"CMAR"},{"issue":"9","key":"2256_CR39","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019;8:(9):957. doi:10.3390\/cells8090957 PubMed PMID: 31443516; PubMed Central PMCID: PMC6770896.","journal-title":"Cells"},{"key":"2256_CR40","doi-asserted-by":"publisher","first-page":"14228","DOI":"10.1038\/ncomms14228","volume":"8","author":"Y Wu","year":"2017","unstructured":"Wu Y, Wang Y, Lin Y, Liu Y, Wang Y, Jia J, et al. Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun. 2017;8:14228. https:\/\/doi.org\/10.1038\/ncomms14228 . PubMed PMID: 28198361; PubMed Central PMCID: PMC5316870.","journal-title":"Nat Commun"},{"issue":"5","key":"2256_CR41","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.3892\/ijmm.2018.3816","volume":"42","author":"Y Xu","year":"2018","unstructured":"Xu Y, Luo Y, Liang C. A regulation loop between Nrf1\u03b1 and MRTF-A controls migration and invasion in MDA-MB-231 breast cancer cells. Int J Mol Med. 2018;42(5):2459. https:\/\/doi.org\/10.3892\/ijmm.2018.3816.","journal-title":"Int J Mol Med"},{"issue":"5","key":"2256_CR42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.molcel.2012.12.006","volume":"49","author":"SY Wu","year":"2013","unstructured":"Wu SY, Lee AY, Lai HT, Zhang H, Chiang CM. Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting. Mol Cell. 2013;49(5):843\u201357. https:\/\/doi.org\/10.1016\/j.molcel.2012.12.006.","journal-title":"Mol Cell"},{"issue":"11","key":"2256_CR43","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.15252\/embj.201591616","volume":"34","author":"M Serrano","year":"2015","unstructured":"Serrano M. SHP2: a new target for pro-senescence cancer therapies. EMBO J. 2015;34(11):1439\u201341. https:\/\/doi.org\/10.15252\/embj.201591616.","journal-title":"EMBO J"},{"issue":"10","key":"2256_CR44","doi-asserted-by":"publisher","first-page":"8319","DOI":"10.1007\/s11033-023-08718-5","volume":"50","author":"A Sharifhoseini","year":"2023","unstructured":"Sharifhoseini A, Heshmati M, Soltani A, Entezam M, Shirzad H, Sedehi M, et al. Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells. Mol Biol Rep. 2023;50(10):8319\u201328. https:\/\/doi.org\/10.1007\/s11033-023-08718-5.","journal-title":"Mol Biol Rep"},{"issue":"3","key":"2256_CR45","doi-asserted-by":"publisher","first-page":"eabc4897","DOI":"10.1126\/sciadv.abc4897","volume":"7","author":"CM Dowling","year":"2021","unstructured":"Dowling CM, Hollinshead KER, Di Grande A, Pritchard J, Zhang H, Dillon ET, et al. Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Sci Adv. 2021;7(3):eabc4897. https:\/\/doi.org\/10.1126\/sciadv.abc4897.","journal-title":"Sci Adv"},{"issue":"9","key":"2256_CR46","first-page":"3810","volume":"61","author":"R Romieu-Mourez","year":"2001","unstructured":"Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE. Roles of IKK Kinases and Protein Kinase CK2 in Activation of Nuclear Factor-\u03baB in Breast Cancer1. Cancer Res. 2001;61(9):3810\u20138.","journal-title":"Cancer Res"},{"issue":"24","key":"2256_CR47","doi-asserted-by":"publisher","first-page":"11375","DOI":"10.1158\/0008-5472.CAN-05-1602","volume":"65","author":"SF Eddy","year":"2005","unstructured":"Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, et al. Inducible I\u03baB Kinase\/I\u03baB Kinase \u03b5 Expression Is Induced by CK2 and Promotes Aberrant Nuclear Factor-\u03baB Activation in Breast Cancer Cells. Cancer Res. 2005;65(24):11375\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1602.","journal-title":"Cancer Res"},{"issue":"1","key":"2256_CR48","doi-asserted-by":"publisher","first-page":"2300061","DOI":"10.1002\/prca.202300061","volume":"18","author":"D Zhang","year":"2024","unstructured":"Zhang D, Shi X, Zheng W, Zhang X, Chen Y. Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells. Proteom \u2013 Clin Appl. 2024;18(1):2300061. https:\/\/doi.org\/10.1002\/prca.202300061.","journal-title":"Proteom \u2013 Clin Appl"},{"issue":"1","key":"2256_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bbrc.2011.10.046","volume":"415","author":"D Drygin","year":"2011","unstructured":"Drygin D, Ho CB, Omori M, Bliesath J, Proffitt C, Rice R, et al. Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochem Biophys Res Commun. 2011;415(1):163\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2011.10.046.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2256_CR50","doi-asserted-by":"publisher","first-page":"e11987","DOI":"10.15252\/emmm.202011987","volume":"12","author":"D Zecchin","year":"2020","unstructured":"Zecchin D, Moore C, Michailidis F, Horswell S, Rana S, Howell M, et al. Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN\u2010null triple negative breast cancer. EMBO Mol Med. 2020;12(8):e11987. https:\/\/doi.org\/10.15252\/emmm.202011987.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"2256_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/biomedicines11092406","volume":"11","author":"C Lefebvre","year":"2023","unstructured":"Lefebvre C, Pellizzari S, Bhat V, Jurcic K, Litchfield DW, Allan AL. Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines. Biomedicines. 2023;11(9):9. https:\/\/doi.org\/10.3390\/biomedicines11092406.","journal-title":"Biomedicines"},{"key":"2256_CR52","doi-asserted-by":"crossref","unstructured":"Tsuchiya Y, Taniguchi,Hiroaki I, Yoshiyuki, Morita, Tomoko, Karim M, Rezaul et al. Ohtake, Norihito,. The Casein Kinase 2-Nrf1 Axis Controls the Clearance of Ubiquitinated Proteins by Regulating Proteasome Gene Expression. Molecular and Cellular Biology. 2013;33(17):3461\u201372. 10.1128\/MCB.01271-12 PubMed PMID: 23816881.","DOI":"10.1128\/MCB.01271-12"},{"issue":"8","key":"2256_CR53","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1096\/fba.2021-00113","volume":"4","author":"D Gau","year":"2022","unstructured":"Gau D, Chawla P, Eder I, Roy P. Myocardin-related transcription factor\u2019s interaction with serum-response factor is critical for outgrowth initiation, progression, and metastatic colonization of breast cancer cells. FASEB BioAdvances. 2022;4(8):509\u201323. https:\/\/doi.org\/10.1096\/fba.2021-00113.","journal-title":"FASEB BioAdvances"},{"key":"2256_CR54","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.biopha.2018.05.092","volume":"104","author":"C Meng","year":"2018","unstructured":"Meng C, He Y, Wei Z, Lu Y, Du F, Ou G, et al. MRTF-A mediates the activation of COL1A1 expression stimulated by multiple signaling pathways in human breast cancer cells. Biomed Pharmacother. 2018;104:718\u201328. https:\/\/doi.org\/10.1016\/j.biopha.2018.05.092.","journal-title":"Biomed Pharmacother"},{"issue":"24","key":"2256_CR55","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1158\/1078-0432.CCR-18-0517","volume":"24","author":"O M\u00e9ndez","year":"2018","unstructured":"M\u00e9ndez O, Peg V, Salvans C, Pujals M, Fern\u00e1ndez Y, Abasolo I, et al. Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. Clin Cancer Res. 2018;24(24):6367\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0517.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2256_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-024-00687-7","volume":"10","author":"O Balcioglu","year":"2024","unstructured":"Balcioglu O, Gates BL, Freeman DW, Hagos BM, Mehrabad EM, Ayala-Talavera D, et al. Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src\/Akt\/Stat3 attenuation. npj Breast Cancer. 2024;10(1):1\u201313. https:\/\/doi.org\/10.1038\/s41523-024-00687-7.","journal-title":"npj Breast Cancer"},{"key":"2256_CR57","doi-asserted-by":"publisher","first-page":"140374","DOI":"10.1016\/j.ijbiomac.2025.140374","volume":"301","author":"YB Cho","year":"2025","unstructured":"Cho YB, Ko IY, Kim HJ, Kim JW, Heo K, Na HJ, et al. Functional epitope mapping of cell surface glucose-regulated protein 94: A combinatorial approach for therapeutic targeting. Int J Biol Macromol. 2025;301:140374. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.140374.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"2256_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-024-01956-x","volume":"10","author":"HY Kim","year":"2024","unstructured":"Kim HY, Kim YM, Hong S. CK2\u03b1-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer. Cell Death Discov. 2024;10(1):1\u201314. https:\/\/doi.org\/10.1038\/s41420-024-01956-x.","journal-title":"Cell Death Discov"},{"key":"2256_CR59","doi-asserted-by":"publisher","first-page":"106986","DOI":"10.1016\/j.phrs.2023.106986","volume":"198","author":"W Zheng","year":"2023","unstructured":"Zheng W, Shen P, Yu C, Tang Y, Qian C, Yang C, et al. Ginsenoside Rh1, a novel casein kinase II subunit alpha (CK2\u03b1) inhibitor, retards metastasis via disrupting HHEX\/CCL20 signaling cascade involved in tumor cell extravasation across endothelial barrier. Pharmacol Res. 2023;198:106986. https:\/\/doi.org\/10.1016\/j.phrs.2023.106986.","journal-title":"Pharmacol Res"},{"issue":"58","key":"2256_CR60","doi-asserted-by":"publisher","first-page":"98495","DOI":"10.18632\/oncotarget.21913","volume":"8","author":"D Andrade","year":"2017","unstructured":"Andrade D, Mehta M, Griffith J, Panneerselvam J, Srivastava A, Kim TD, et al. YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways. Oncotarget. 2017;8(58):98495\u2013508. https:\/\/doi.org\/10.18632\/oncotarget.21913.","journal-title":"Oncotarget"},{"issue":"1","key":"2256_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-024-07323-z","volume":"16","author":"L Huang","year":"2025","unstructured":"Huang L, Wen Y, Guo Q, Zhang C, Yang X, Li M, et al. CK2\u03b1-mediated phosphorylation of DUB3 promotes YAP1 stability and oncogenic functions. Cell Death Dis. 2025;16(1):1\u201314. https:\/\/doi.org\/10.1038\/s41419-024-07323-z.","journal-title":"Cell Death Dis"},{"key":"2256_CR62","doi-asserted-by":"publisher","first-page":"114822","DOI":"10.1016\/j.biopha.2023.114822","volume":"163","author":"E Pavitra","year":"2023","unstructured":"Pavitra E, Kancharla J, Gupta VK, Prasad K, Sung JY, Kim J, et al. The role of NF-\u03baB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy. Biomed Pharmacother. 2023;163:114822. https:\/\/doi.org\/10.1016\/j.biopha.2023.114822.","journal-title":"Biomed Pharmacother"},{"issue":"21","key":"2256_CR63","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1182\/blood.V116.21.787.787","volume":"116","author":"C Ho","year":"2010","unstructured":"Ho C, Rice R, Drygin D, Bliesath J, Streiner N, Siddiqui-Jain A, et al. CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K\/Akt, JAK-STAT and NF-\u03baB Signaling and Induces Apoptosis In Multiple Myeloma Cells. Blood. 2010;116(21):787. https:\/\/doi.org\/10.1182\/blood.V116.21.787.787.","journal-title":"Blood"},{"issue":"4","key":"2256_CR64","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/bcr2886","volume":"13","author":"K Shostak","year":"2011","unstructured":"Shostak K, Chariot A. NF-\u03baB, stem cells and breast cancer: the links get stronger. Breast Cancer Res. 2011;13(4):214. https:\/\/doi.org\/10.1186\/bcr2886.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2256_CR65","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12964-020-00613-x","volume":"18","author":"M Wang","year":"2020","unstructured":"Wang M, Zhang Y, Xu Z, Qian P, Sun W, Wang X, et al. RelB sustains endocrine resistant malignancy: an insight of noncanonical NF-\u03baB pathway into breast Cancer progression. Cell Commun Signal. 2020;18(1):128. https:\/\/doi.org\/10.1186\/s12964-020-00613-x.","journal-title":"Cell Commun Signal"},{"issue":"9","key":"2256_CR66","doi-asserted-by":"publisher","first-page":"e75280","DOI":"10.1371\/journal.pone.0075280","volume":"8","author":"S Manni","year":"2013","unstructured":"Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A, Pizzi M, et al. Protein Kinase CK2 Inhibition Down Modulates the NF-\u03baB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE. 2013;8(9):e75280. https:\/\/doi.org\/10.1371\/journal.pone.0075280.","journal-title":"PLoS ONE"},{"issue":"2","key":"2256_CR67","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.18632\/oncotarget.6361","volume":"7","author":"F Buontempo","year":"2015","unstructured":"Buontempo F, Orsini E, Lonetti A, Cappellini A, Chiarini F, Evangelisti C, et al. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP\/Grp78 and turning on the proapoptotic NF\u00ceoB. Oncotarget. 2015;7(2):1323\u201340. https:\/\/doi.org\/10.18632\/oncotarget.6361.","journal-title":"Oncotarget"},{"key":"2256_CR68","doi-asserted-by":"publisher","unstructured":"Zhang Hping, Jiang R, yuan, Zhu Jyu, Sun K na, Huang Y, Zhou H, huan et al. PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. 2024;31(4):539\u201351. https:\/\/doi.org\/10.1007\/s12282-024-01567-5 PubMed PMID: 38630392; PubMed Central PMCID: PMC11194209.","DOI":"10.1007\/s12282-024-01567-5"},{"issue":"12","key":"2256_CR69","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.neo.2021.10.003","volume":"23","author":"I To\u0161i\u0107","year":"2021","unstructured":"To\u0161i\u0107 I, Frank DA. STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications. Neoplasia. 2021;23(12):1167\u201378. https:\/\/doi.org\/10.1016\/j.neo.2021.10.003.","journal-title":"Neoplasia"},{"issue":"20","key":"2256_CR70","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1007\/s00018-009-0108-1","volume":"66","author":"G Di Maira","year":"2009","unstructured":"Di Maira G, Brustolon F, Pinna LA, Ruzzene M. Dephosphorylation and inactivation of Akt\/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci. 2009;66(20):3363\u201373. https:\/\/doi.org\/10.1007\/s00018-009-0108-1.","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"2256_CR71","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/sj.cdd.4401604","volume":"12","author":"G Di Maira","year":"2005","unstructured":"Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, et al. Protein kinase CK2 phosphorylates and upregulates Akt\/PKB. Cell Death Differ. 2005;12(6):668\u201377. https:\/\/doi.org\/10.1038\/sj.cdd.4401604.","journal-title":"Cell Death Differ"},{"issue":"13","key":"2256_CR72","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.3390\/cancers17132232","volume":"17","author":"A Hassan","year":"2025","unstructured":"Hassan A, Aubel C. The PI3K\/Akt\/mTOR Signaling Pathway in Triple-Negative Breast Cancer: A Resistance Pathway and a Prime Target for Targeted Therapies. Cancers. 2025;17(13):2232. https:\/\/doi.org\/10.3390\/cancers17132232.","journal-title":"Cancers"},{"issue":"3","key":"2256_CR73","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","volume":"20","author":"M Dance","year":"2008","unstructured":"Dance M, Montagner A, Salles JP, Yart A, Raynal P. The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway. Cell Signal. 2008;20(3):453\u20139. https:\/\/doi.org\/10.1016\/j.cellsig.2007.10.002.","journal-title":"Cell Signal"},{"key":"2256_CR74","doi-asserted-by":"publisher","unstructured":"Grossmann KS, Ros\u00e1rio M, Birchmeier C, Birchmeier W. Chapter 2 - The Tyrosine Phosphatase Shp2 in Development and Cancer. In: Vande Woude GF, Klein G, editors. Advances in Cancer Research [Internet]. Academic Press; 2010 [cited 2026 Jun 11]. pp. 53\u201389. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0065230X10060021https:\/\/doi.org\/10.1016\/S0065-230X(10)06002-1","DOI":"10.1016\/S0065-230X(10)06002-1"},{"issue":"1","key":"2256_CR75","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","volume":"26","author":"TA Ahmed","year":"2019","unstructured":"Ahmed TA, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson SA, et al. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Cell Rep. 2019;26(1):65\u2013e785. https:\/\/doi.org\/10.1016\/j.celrep.2018.12.013 . PubMed PMID: 30605687.","journal-title":"Cell Rep"},{"issue":"2","key":"2256_CR76","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","volume":"66","author":"R Roskoski","year":"2012","unstructured":"Roskoski R. ERK1\/2 MAP kinases: Structure, function, and regulation. Pharmacol Res. 2012;66(2):105\u201343. https:\/\/doi.org\/10.1016\/j.phrs.2012.04.005.","journal-title":"Pharmacol Res"},{"issue":"2","key":"2256_CR77","doi-asserted-by":"publisher","first-page":"366","DOI":"10.33594\/000000144","volume":"53","author":"A Plotnikov","year":"2019","unstructured":"Plotnikov A, Chuderland D, Karamansha Y, Livnah O, Seger R. Nuclear ERK Translocation is Mediated by Protein Kinase CK2 and Accelerated by Autophosphorylation | Cell Physiol Biochem. Cell Physiol Biochem. 2019;53(2):366\u201387.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"2256_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00259-8","volume":"5","author":"Z Wang","year":"2020","unstructured":"Wang Z, Xu Q, Zhang N, Du X, Xu G, Yan X. CD146, from a melanoma cell adhesion molecule to a signaling receptor. Sig Transduct Target Ther. 2020;5(1):1\u201315. https:\/\/doi.org\/10.1038\/s41392-020-00259-8.","journal-title":"Sig Transduct Target Ther"},{"issue":"3","key":"2256_CR79","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.bbamcr.2011.10.013","volume":"1823","author":"M Marzec","year":"2012","unstructured":"Marzec M, Eletto D, Argon Y. GRP94: an HSP90-like protein specialized for protein folding and quality control in the Endoplasmic Reticulum. Biochim Biophys Acta. 2012;1823(3):774\u201387. https:\/\/doi.org\/10.1016\/j.bbamcr.2011.10.013 . PubMed PMID: 22079671; PubMed Central PMCID: PMC3443595.","journal-title":"Biochim Biophys Acta"},{"key":"2256_CR80","doi-asserted-by":"publisher","unstructured":"Duan X, Iwanowycz S, Ngoi S, Hill M, Zhao Q, Liu B. Molecular Chaperone GRP94\/GP96 in Cancers: Oncogenesis and Therapeutic Target. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.629846.","DOI":"10.3389\/fonc.2021.629846"},{"issue":"5","key":"2256_CR81","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/s1359-6101","volume":"14","author":"E Schutyser","year":"2003","unstructured":"Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14(5):409\u201326. https:\/\/doi.org\/10.1016\/s1359-6101. (03)00049-2 PubMed PMID: 12948524.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"2256_CR82","doi-asserted-by":"publisher","first-page":"e2005869","DOI":"10.1371\/journal.pbio.2005869","volume":"16","author":"W Chen","year":"2018","unstructured":"Chen W, Qin Y, Wang D, Zhou L, Liu Y, Chen S, et al. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018;16(7):e2005869. https:\/\/doi.org\/10.1371\/journal.pbio.2005869.","journal-title":"PLoS Biol"},{"issue":"23","key":"2256_CR83","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms232315163","volume":"23","author":"JX Zhou","year":"2022","unstructured":"Zhou JX, Agborbesong E, Li LX, Li X. Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression. Int J Mol Sci. 2022;23(23):23. https:\/\/doi.org\/10.3390\/ijms232315163.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2256_CR84","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1101\/gad.1286005","volume":"19","author":"X Zhang","year":"2005","unstructured":"Zhang X, Ozawa Y, Lee H, Wen YD, Tan TH, Wadzinski BE, et al. Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine\/threonine phosphatase 4. Genes Dev. 2005;19(7):827\u201339. https:\/\/doi.org\/10.1101\/gad.1286005.","journal-title":"Genes Dev"},{"issue":"9","key":"2256_CR85","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1242\/jcs.081778","volume":"124","author":"M Watabe","year":"2011","unstructured":"Watabe M, Nakaki T. Protein kinase CK2 regulates the formation and clearance of aggresomes in response to stress. J Cell Sci. 2011;124(9):1519\u201332. https:\/\/doi.org\/10.1242\/jcs.081778.","journal-title":"J Cell Sci"},{"issue":"1","key":"2256_CR86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.maturitas.2015.01.015","volume":"81","author":"S Tangutoori","year":"2015","unstructured":"Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: A new era of targeted therapy. Maturitas. 2015;81(1):5\u20139. https:\/\/doi.org\/10.1016\/j.maturitas.2015.01.015.","journal-title":"Maturitas"},{"issue":"1","key":"2256_CR87","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.seminoncol.2023.08.001","volume":"PARP Inhibitors","author":"PB Kanev","year":"2024","unstructured":"Kanev PB, Atemin A, Stoynov S, Aleksandrov R. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance. Semin Oncol. 2024;PARP Inhibitors51(1):2\u201318. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.08.001.","journal-title":"Semin Oncol"},{"key":"2256_CR88","unstructured":"Yu WH. Development Of Rational Combination Therapy With Parp Inhibitors And Kinase Inhibitors In Tnbc. Dissertations & Theses (Open Access) [Internet]. 2016 Aug 1. Available from: https:\/\/digitalcommons.library.tmc.edu\/utgsbs_dissertations\/682"},{"issue":"40","key":"2256_CR89","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1038\/s41388-023-02812-5","volume":"42","author":"C Wang","year":"2023","unstructured":"Wang C, Tian L, He Q, Lin S, Wu Y, Qiao Y, et al. Targeting CK2-mediated phosphorylation of p53R2 sensitizes BRCA-proficient cancer cells to PARP inhibitors. Oncogene. 2023;42(40):2971\u201384. https:\/\/doi.org\/10.1038\/s41388-023-02812-5.","journal-title":"Oncogene"},{"key":"2256_CR90","doi-asserted-by":"publisher","unstructured":"Guo Q, Zhao J, Li Y, Zhang C, Shen X, Liu L, et al. CK2\u2013HTATSF1\u2013TOPBP1 signaling axis modulates tumor chemotherapy response. J Biol Chem. 2024;300(6). https:\/\/doi.org\/10.1016\/j.jbc.2024.107377 . PubMed PMID: 38762174.","DOI":"10.1016\/j.jbc.2024.107377"},{"key":"2256_CR91","doi-asserted-by":"publisher","first-page":"104880","DOI":"10.1016\/j.phrs.2020.104880","volume":"158","author":"S Sinha","year":"2020","unstructured":"Sinha S, Sharma S, Vora J, Shrivastava N. Emerging role of sirtuins in breast cancer metastasis and multidrug resistance: Implication for novel therapeutic strategies targeting sirtuins. Pharmacol Res. 2020;158:104880. https:\/\/doi.org\/10.1016\/j.phrs.2020.104880.","journal-title":"Pharmacol Res"},{"issue":"12","key":"2256_CR92","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1016\/j.ajpath.2016.08.007","volume":"186","author":"JS Bae","year":"2016","unstructured":"Bae JS, Park SH, Jamiyandorj U, Kim KM, Noh SJ, Kim JR, et al. CK2\u03b1\/CSNK2A1 Phosphorylates SIRT6 and Is Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of Diagnosed Patients. Am J Pathol. 2016;186(12):3297\u2013315. https:\/\/doi.org\/10.1016\/j.ajpath.2016.08.007.","journal-title":"Am J Pathol"},{"issue":"8","key":"2256_CR93","doi-asserted-by":"publisher","first-page":"e6611","DOI":"10.1371\/journal.pone.0006611","volume":"4","author":"H Kang","year":"2009","unstructured":"Kang H, Jung JW, Kim MK, Chung JH. CK2 Is the Regulator of SIRT1 Substrate-Binding Affinity, Deacetylase Activity and Cellular Response to DNA-Damage. PLoS ONE. 2009;4(8):e6611. https:\/\/doi.org\/10.1371\/journal.pone.0006611.","journal-title":"PLoS ONE"},{"key":"2256_CR94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-4615","volume":"1","author":"M Hatakeyama","year":"1995","unstructured":"Hatakeyama M, Weinberg RA. The role of RB in cell cycle control. Prog Cell Cycle Res. 1995;1:9\u201319. https:\/\/doi.org\/10.1007\/978-1-4615-1809-9_2. 1809-9_2 PubMed PMID: 9552350.","journal-title":"Prog Cell Cycle Res"},{"issue":"7","key":"2256_CR95","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1177\/153537020623100713","volume":"231","author":"ES Knudsen","year":"2006","unstructured":"Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med (Maywood). 2006;231(7):1271\u201381. doi:10.1177\/153537020623100713 PubMed PMID: 16816134.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"9","key":"2256_CR96","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc2399","volume":"8","author":"DL Burkhart","year":"2008","unstructured":"Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671\u201382. doi:10.1038\/nrc2399 PubMed PMID: 18650841; PubMed Central PMCID: PMC6996492.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"2256_CR97","doi-asserted-by":"publisher","first-page":"eadj1564","DOI":"10.1126\/sciadv.adj1564","volume":"10","author":"D Bulanova","year":"2024","unstructured":"Bulanova D, Akimov Y, Senkowski W, Oikkonen J, Gall-Mas L, Timonen S, et al. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. Sci Adv. 2024;10(21):eadj1564. https:\/\/doi.org\/10.1126\/sciadv.adj1564 . PubMed PMID: 38781347; PubMed Central PMCID: PMC11114247.","journal-title":"Sci Adv"},{"issue":"1","key":"2256_CR98","doi-asserted-by":"publisher","first-page":"14689","DOI":"10.1038\/s41598-020-71854-6","volume":"10","author":"MF Gottardo","year":"2020","unstructured":"Gottardo MF, Capobianco CS, Sidabra JE, Garona J, Perera Y, Perea SE, et al. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization. Sci Rep. 2020;10(1):14689. https:\/\/doi.org\/10.1038\/s41598-020-71854-6.","journal-title":"Sci Rep"},{"key":"2256_CR99","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.17179\/excli2020-2363","volume":"19","author":"SKL Karna","year":"2020","unstructured":"Karna SKL, Lone BA, Ahmad F, Shahi N, Pokharel YR. Knockdown of CSNK2\u03b2 suppresses MDA-MB231 cell growth, induces apoptosis, inhibits migration and invasion. EXCLI J. 2020;19:1211\u201326. https:\/\/doi.org\/10.17179\/excli2020-2363.","journal-title":"EXCLI J"},{"issue":"26","key":"2256_CR100","doi-asserted-by":"publisher","first-page":"40846","DOI":"10.18632\/oncotarget.8519","volume":"7","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Shen JK, Hornicek FJ, Kan Q, Duan Z. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer. Oncotarget. 2016;7(26):40846\u201359. https:\/\/doi.org\/10.18632\/oncotarget.8519.","journal-title":"Oncotarget"},{"issue":"1","key":"2256_CR101","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13058-015-0524-0","volume":"17","author":"BT Kren","year":"2015","unstructured":"Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, et al. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy. Breast Cancer Res. 2015;17(1):19. https:\/\/doi.org\/10.1186\/s13058-015-0524-0.","journal-title":"Breast Cancer Res"},{"issue":"4Supplement","key":"2256_CR102","doi-asserted-by":"publisher","first-page":"PD3","DOI":"10.1158\/1538-7445.SABCS21-PD3-08","volume":"82","author":"K Sato","year":"2022","unstructured":"Sato K, Baker SJ, Reddy EP, Irie HY. Abstract PD3-08: Novel cancer stem cell inhibitor 108600 modulates tumor immunomicroenvironment of triple negative breast cancer (TNBC). Cancer Res. 2022;82(4Supplement):PD3\u201308. https:\/\/doi.org\/10.1158\/1538-7445.SABCS21-PD3-08.","journal-title":"Cancer Res"},{"key":"2256_CR103","doi-asserted-by":"publisher","unstructured":"Kaur S, Reginauld B, Razjooyan S, Phi T, Singh SP, Meyer TJ, et al. Effects of a humanized CD47 antibody and recombinant SIRP\u03b1 proteins on triple negative breast carcinoma stem cells. Front Cell Dev Biol. 2024;12. https:\/\/doi.org\/10.3389\/fcell.2024.1356421.","DOI":"10.3389\/fcell.2024.1356421"},{"issue":"11","key":"2256_CR104","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/onc.2011.338","volume":"31","author":"O Leis","year":"2012","unstructured":"Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31(11):1354\u201365. https:\/\/doi.org\/10.1038\/onc.2011.338.","journal-title":"Oncogene"},{"issue":"1","key":"2256_CR105","doi-asserted-by":"publisher","first-page":"9170","DOI":"10.1038\/s41598-017-08971-2","volume":"7","author":"P Mukherjee","year":"2017","unstructured":"Mukherjee P, Gupta A, Chattopadhyay D, Chatterji U. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells. Sci Rep. 2017;7(1):9170. https:\/\/doi.org\/10.1038\/s41598-017-08971-2.","journal-title":"Sci Rep"},{"issue":"22","key":"2256_CR106","doi-asserted-by":"publisher","first-page":"36305","DOI":"10.18632\/oncotarget.16750","volume":"8","author":"JM Gwak","year":"2017","unstructured":"Gwak JM, Kim M, Kim HJ, Jang MH, Park SY. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance. Oncotarget. 2017;8(22):36305\u201318. https:\/\/doi.org\/10.18632\/oncotarget.16750.","journal-title":"Oncotarget"},{"issue":"2","key":"2256_CR107","doi-asserted-by":"publisher","first-page":"321","DOI":"10.20517\/cdr.2020.106","volume":"4","author":"N Fultang","year":"2021","unstructured":"Fultang N, Chakraborty M, Peethambaran B. Regulation of cancer stem cells in triple negative breast cancer. cdr. 2021;4(2):321\u201342. https:\/\/doi.org\/10.20517\/cdr.2020.106.","journal-title":"cdr"},{"issue":"28","key":"2256_CR108","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1038\/onc.2014.299","volume":"34","author":"RT Nitta","year":"2015","unstructured":"Nitta RT, Gholamin S, Feroze AH, Agarwal M, Cheshier SH, Mitra SS, et al. Casein kinase 2\u03b1 regulates glioblastoma brain tumor-initiating cell growth through the \u03b2-catenin pathway. Oncogene. 2015;34(28):3688\u201399. https:\/\/doi.org\/10.1038\/onc.2014.299.","journal-title":"Oncogene"},{"key":"2256_CR109","doi-asserted-by":"publisher","unstructured":"Silva-Pavez E, Tapia JC. Protein Kinase CK2 in Cancer Energetics. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/fonc.2020.00893.","DOI":"10.3389\/fonc.2020.00893"},{"issue":"15","key":"2256_CR110","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.18632\/oncotarget.2248","volume":"5","author":"GK Gray","year":"2014","unstructured":"Gray GK, McFarland BC, Rowse AL, Gibson SA, Benveniste EN. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells. Oncotarget. 2014;5(15):6484\u201396. https:\/\/doi.org\/10.18632\/oncotarget.2248 . PubMed PMID: 25153725; PubMed Central PMCID: PMC4171645.","journal-title":"Oncotarget"},{"issue":"2","key":"2256_CR111","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/stem.1281","volume":"31","author":"J Yang","year":"2013","unstructured":"Yang J, Liao D, Chen C, Liu Y, Chuang TH, Xiang R, et al. Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR\/Stat3\/Sox-2 Signaling Pathway. Stem Cells. 2013;31(2):248\u201358. https:\/\/doi.org\/10.1002\/stem.1281.","journal-title":"Stem Cells"},{"issue":"8","key":"2256_CR112","doi-asserted-by":"publisher","first-page":"e1001376","DOI":"10.1371\/journal.pbio.1001376","volume":"10","author":"A Shkoda","year":"2012","unstructured":"Shkoda A, Town JA, Griese J, Romio M, Sarioglu H, Kn\u00f6fel T, et al. The Germinal Center Kinase TNIK Is Required for Canonical NF-\u03baB and JNK Signaling in B-Cells by the EBV Oncoprotein LMP1 and the CD40 Receptor. PLoS Biol. 2012;10(8):e1001376. https:\/\/doi.org\/10.1371\/journal.pbio.1001376.","journal-title":"PLoS Biol"},{"issue":"1","key":"2256_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-024-00614-w","volume":"8","author":"AJ Laham","year":"2024","unstructured":"Laham AJ, El-Awady R, Saber-Ayad M, Wang N, Yan G, Boudreault J, et al. Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1\/S targeting chemotherapy drugs. npj Precis Onc. 2024;8(1):1\u201314. https:\/\/doi.org\/10.1038\/s41698-024-00614-w.","journal-title":"npj Precis Onc"},{"issue":"11","key":"2256_CR114","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1158\/0008-5472.CAN-21-2300","volume":"82","author":"X Zhao","year":"2022","unstructured":"Zhao X, Wei Y, Chu YY, Li Y, Hsu JM, Jiang Z, et al. Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. Cancer Res. 2022;82(11):2185\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2300.","journal-title":"Cancer Res"},{"key":"2256_CR115","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer."},{"key":"2256_CR116","doi-asserted-by":"publisher","unstructured":"Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.964442.","DOI":"10.3389\/fimmu.2022.964442"},{"key":"2256_CR117","doi-asserted-by":"publisher","unstructured":"PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis: Climacteric. Vol 26, No 2 - Get Access. Climacteric [Internet]. [cited 2026 Jun 7]. Available from: https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/13697137.2023.2170225","DOI":"10.1080\/13697137.2023.2170225"},{"key":"2256_CR118","doi-asserted-by":"publisher","unstructured":"Tabnak P, Ebrahimnezhad M, HajiEsmailPoor Z. Genetic mutations governing ferroptosis sensitivity and resistance: a precision approach to cancer therapy. Cell Death Dis 2026 May 7. https:\/\/doi.org\/10.1038\/s41419-026-08796-w","DOI":"10.1038\/s41419-026-08796-w"},{"issue":"210","key":"2256_CR119","doi-asserted-by":"publisher","first-page":"ra11","DOI":"10.1126\/scisignal.2002585","volume":"5","author":"KM Taylor","year":"2012","unstructured":"Taylor KM, Hiscox S, Nicholson RI, Hogstrand C, Kille P. Protein Kinase CK2 Triggers Cytosolic Zinc Signaling Pathways by Phosphorylation of Zinc Channel ZIP7. Sci Signal. 2012;5(210):ra11\u201311. https:\/\/doi.org\/10.1126\/scisignal.2002585.","journal-title":"Sci Signal"},{"issue":"6","key":"2256_CR120","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10534-019-00218-z","volume":"32","author":"MS Zaman","year":"2019","unstructured":"Zaman MS, Johnson AJ, Petersingham G, Muench GW, Dong Q, Wu MJ. Protein kinase CK2 is involved in zinc homeostasis in breast and prostate cancer cells. Biometals. 2019;32(6):861\u201373. https:\/\/doi.org\/10.1007\/s10534-019-00218-z.","journal-title":"Biometals"},{"key":"2256_CR121","doi-asserted-by":"publisher","unstructured":"Chojnowski JE, Li R, Tsang T, Alfaran FH, Dick A, Cocklin S, et al. Copper Modulates the Catalytic Activity of Protein Kinase CK2. Front Mol Biosci. 2022;9. https:\/\/doi.org\/10.3389\/fmolb.2022.878652.","DOI":"10.3389\/fmolb.2022.878652"},{"key":"2256_CR122","doi-asserted-by":"publisher","first-page":"122972","DOI":"10.1016\/j.lfs.2024.122972","volume":"354","author":"A Focaccio","year":"2024","unstructured":"Focaccio A, Rossi L, De Luca A. A spotlight on the role of copper in the epithelial to mesenchymal transition. Life Sci. 2024;354:122972. https:\/\/doi.org\/10.1016\/j.lfs.2024.122972.","journal-title":"Life Sci"},{"key":"2256_CR123","unstructured":"Ryan C. Silmitasertib Drives Disease Control in Advanced Basal Cell Carcinoma | OncLive [Internet]. 2026 [cited 2026 Jun 8]. Available from: https:\/\/www.onclive.com\/view\/silmitasertib-drives-disease-control-in-advanced-basal-cell-carcinoma"},{"issue":"10","key":"2256_CR124","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/bjc.2015.137","volume":"112","author":"MR Sarduy","year":"2015","unstructured":"Sarduy MR, Garc\u00eda I, Coca MA, Perera A, Torres LA, Valenzuela CM, et al. Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer. Br J Cancer. 2015;112(10):1636\u201343. https:\/\/doi.org\/10.1038\/bjc.2015.137.","journal-title":"Br J Cancer"},{"issue":"2","key":"2256_CR125","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41419-019-1306-x","volume":"10","author":"E Silva-Pavez","year":"2019","unstructured":"Silva-Pavez E, Villar P, Trigo C, Caama\u00f1o E, Niechi I, P\u00e9rez P, et al. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells. Cell Death Dis. 2019;10(2):73. https:\/\/doi.org\/10.1038\/s41419-019-1306-x.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2256_CR126","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hep.32804","volume":"77","author":"MJ Borad","year":"2023","unstructured":"Borad MJ, Bai LY, Richards D, Mody K, Hubbard J, Rha SY, et al. Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced\/metastatic cholangiocarcinoma: A Phase 1b\/2 study. Hepatology. 2023;77(3):760. https:\/\/doi.org\/10.1002\/hep.32804.","journal-title":"Hepatology"},{"issue":"19","key":"2256_CR127","doi-asserted-by":"publisher","first-page":"20702","DOI":"10.1021\/acsomega.3c10478","volume":"9","author":"MA Al-Qadhi","year":"2024","unstructured":"Al-Qadhi MA, Yahya TAA, El-Nassan HB. Recent Advances in the Discovery of CK2 Inhibitors. ACS Omega. 2024;9(19):20702\u201319. https:\/\/doi.org\/10.1021\/acsomega.3c10478.","journal-title":"ACS Omega"},{"issue":"1","key":"2256_CR128","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ph10010011","volume":"10","author":"C Franchin","year":"2017","unstructured":"Franchin C, Borgo C, Zaramella S, Cesaro L, Arrigoni G, Salvi M, et al. Exploring the CK2 Paradox: Restless. Danger Dispensable Pharmaceuticals. 2017;10(1):11. https:\/\/doi.org\/10.3390\/ph10010011.","journal-title":"Danger Dispensable Pharmaceuticals"},{"key":"2256_CR129","doi-asserted-by":"publisher","first-page":"100427","DOI":"10.1016\/j.carpta.2024.100427","volume":"7","author":"M Wiranowska","year":"2024","unstructured":"Wiranowska M. Advances in the use of chitosan and chlorotoxin- functionalized chitosan polymers in drug delivery and detection of glioma \u2013 A review. Carbohydr Polym Technol Appl. 2024;7:100427. https:\/\/doi.org\/10.1016\/j.carpta.2024.100427.","journal-title":"Carbohydr Polym Technol Appl"},{"key":"2256_CR130","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jconrel.2016.11.001","volume":"244","author":"ST Chou","year":"2016","unstructured":"Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, et al. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Controlled Release. 2016;244:14\u201323. https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.001.","journal-title":"J Controlled Release"},{"issue":"7","key":"2256_CR131","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/molecules25071497","volume":"25","author":"R Mart\u00ednez","year":"2020","unstructured":"Mart\u00ednez R, Di Geronimo B, Pastor M, Zapico JM, Coderch C, Panchuk R, et al. Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors. Molecules. 2020;25(7):7. https:\/\/doi.org\/10.3390\/molecules25071497.","journal-title":"Molecules"},{"issue":"17","key":"2256_CR132","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1021\/acs.jmedchem.0c00491","volume":"63","author":"T Liu","year":"2020","unstructured":"Liu T, Wan Y, Xiao Y, Xia C, Duan G. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. J Med Chem. 2020;63(17):8977\u20139002. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00491.","journal-title":"J Med Chem"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02256-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02256-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02256-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:03:09Z","timestamp":1790452989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02256-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2256"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02256-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"2 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared that the artificial intelligence-assisted tool was used for language editing and grammatical refinement during the preparation of this manuscript.","order":4,"name":"Ethics","label":"Declaration on the use of artificial intelligence-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"343"}}